Absci (NASDAQ:ABSI) Announces Earnings Results, Meets Expectations

Absci (NASDAQ:ABSI) released its quarterly earnings results on Thursday. The company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19), FiscalAI reports. Absci had a negative return on equity of 61.71% and a negative net margin of 7,756.38%. The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.66 million.

Here are the key takeaways from Absci’s conference call:

• Absci expects to report interim 13-week pattern hair loss data in December 2026 and full 26-week proof-of-concept data in early 2027. Management characterized the interim readout as directional and said it will not change the ongoing trial.
• The company said blinded aggregate data to date show ABS-201 is well tolerated, and its estimated half-life may support two or three injections over six months. These findings are preliminary and do not yet establish efficacy.
• Absci now anticipates starting its planned phase II endometriosis trial in mid-2027, with doses to be selected after reviewing HEADLINE trial data. The company estimates the program could reach more than $4 billion in peak sales if development succeeds.
• Cash, cash equivalents and marketable securities totaled $173.7 million at quarter-end, down from $201.1 million at June 30; management expects funding to last into the second half of 2028. Quarterly R&D expenses rose to $23.6 million from $19.2 million a year earlier, while SG&A increased to $9 million from $8.4 million.
• Management cited consumer research suggesting that 30–35 additional target-area hairs per square centimeter at 26 weeks could support strong adoption, and estimated a $25 billion U.S. pattern hair loss market. These are company estimates based on hypothetical product profiles, not clinical results.

Absci Stock Performance

Shares of ABSI stock traded down $0.38 on Thursday, hitting $9.74. The company had a trading volume of 3,005,329 shares, compared to its average volume of 4,307,210. The firm has a market cap of $1.67 billion, a P/E ratio of -12.24 and a beta of 2.22. The stock’s 50-day moving average is $9.65 and its two-hundred day moving average is $6.75. Absci has a twelve month low of $2.24 and a twelve month high of $12.54.

Key Headlines Impacting Absci

These are some of the ABSI headlines that stood out recently:

• Positive Sentiment: Absci said its Phase 2 HEADLINE trial of ABS-201 for pattern hair loss remains on track, with 13-week proof-of-concept data expected in December 2026 and 26-week results expected in early 2027. The data could be an important clinical catalyst. Absci reports business updates and third-quarter results
• Neutral Sentiment: Absci appointed Gerry Muhle, a former Galderma executive with experience launching prescription biologics, as chief commercial officer. The hire adds commercial expertise, though its impact depends on future pipeline progress. Absci appoints Gerry Muhle as chief commercial officer
• Negative Sentiment: Third-quarter revenue was $0.3 million, below analyst expectations of $0.66 million and down from $0.4 million a year earlier. Net loss widened to $33.3 million from $28.7 million, while research and development spending increased. Although reported EPS of $0.19 loss matched one consensus estimate, another estimate cited by Zacks indicated a modest miss. Absci reports third-quarter earnings results

Analyst Ratings Changes

A number of brokerages recently issued reports on ABSI. BTIG Research set a $15.00 price objective on shares of Absci and gave the company a “buy” rating in a report on Tuesday, September 8th. Guggenheim reissued a “buy” rating on shares of Absci in a report on Monday, September 28th. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Absci in a report on Wednesday, September 23rd. JPMorgan Chase & Co. upped their price target on shares of Absci from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Absci in a research note on Thursday, October 15th. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Absci Company Profile

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.